Vivos Therapeutics, Inc. (VVOS)
Automate Your Wheel Strategy on VVOS
With Tiblio's Option Bot, you can configure your own wheel strategy including VVOS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VVOS
- Rev/Share 1.7019
- Book/Share 0.5127
- PB 4.1738
- Debt/Equity 0.3174
- CurrentRatio 0.7673
- ROIC -1.3767
- MktCap 12603573.0
- FreeCF/Share -1.6271
- PFCF -0.9012
- PE -1.6369
- Debt/Assets 0.124
- DivYield 0
- ROE -1.7043
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Brad Amman - CFO Kirk Huntsman - Chairman and CEO Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2025 Earnings Call.
Read More
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.63 per share a year ago.
Read More
Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025.
Read More
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Vivos Therapeutics (VVOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
About Vivos Therapeutics, Inc. (VVOS)
- IPO Date 2020-12-11
- Website https://vivos.com
- Industry Medical - Devices
- CEO Mr. R. Kirk Huntsman
- Employees 109